{"id":562885,"date":"2021-09-13T18:52:01","date_gmt":"2021-09-13T18:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=562885"},"modified":"2021-09-13T18:52:01","modified_gmt":"2021-09-13T18:52:01","slug":"multiple-myeloma-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/multiple-myeloma-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_562885.html","title":{"rendered":"Multiple Myeloma Market Analysis, Market Size &#038; Share, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1631509311.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Multiple Myeloma Market Analysis, Market Size &amp; Share, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1631509311.png\" alt=\"Multiple Myeloma Market Analysis, Market Size &amp; Share, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast\u20142030\u2019 report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight has launched a new report on<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"> &#8220;Multiple Myeloma &#8211; Market Insights, Epidemiology, and Market Forecast-2030&rdquo;.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-myeloma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;Multiple Myeloma &ndash; Market Insights, Epidemiology, and Market Forecast-2030&Prime;<\/a><\/strong> report deliver an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/e8d02ec0e3e70f903a6d72651eda1ed1.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key facts of the Report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the year 2020, the total incident case of Multiple Myeloma was 91,693 cases in the 8MM and the United States, in 2020, accounted for 32,270 cases (the highest number) which might increase in the forecast period.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the 8MM, the total gender-specific cases of Multiple Myeloma were 43,910 cases for males and 36,805 cases for females in the year 2020&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to DelveInsight&rsquo;s analysis, in the 8MM, China reported the second-highest incident cases of Multiple myeloma, i.e., 21,116 which accounted for nearly 23% of the total 8MM cases, in the year 2020.&nbsp;<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key benefits of the report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Multiple Myeloma&nbsp; market report covers a descriptive overview and comprehensive insight of the Multiple Myeloma&nbsp; epidemiology and Multiple Myeloma&nbsp; market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Multiple Myeloma market report provides insights on the current and emerging therapies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Multiple Myeloma market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Multiple Myeloma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Multiple Myeloma market.<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Got queries? Click here to know more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-myeloma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Multiple Myeloma Market Landscape.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Multiple Myeloma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Multiple Myeloma is a sort of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with Multiple Myeloma, but joint problems can sometimes begin before skin patches appear.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The key players involved in the Multiple Myeloma&nbsp; market:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cartesian Therapeutics,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AbbVie, and Roche,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Janssen,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Biotech\/Nanjing Legend Biotech,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Merck Sharp &amp; Dohme Corp.,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Janssen Research &amp; Development,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regeneron Pharmaceuticals,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bristol-Myers Squibb\/Celgene,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BMS\/ AstraZeneca,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer (Array Biopharma),&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BioLineRx,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MorphoSys AG\/I-Mab Biopharma,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chipscreen Biosciences,<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And others.<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The launch of the emerging therapies is expected to significantly impact the Multiple Myeloma treatment scenario in the upcoming years:-<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Drug covered<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Descartes-11,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Venetoclax,&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ciltacabtagene Autoleucel (cilta-cel\/ JNJ-68284528\/LCAR-B38M),&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Keytruda (Pembrolizumab),&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cetrelimab (JNJ-63723283),&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">REGN5458,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Iberdomide,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Imfinzi (Durvalumab; MEDI4736),&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Braftovi (encorafenib),&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Motixafortide (BL-8040),&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Felzartamab (MOR202),&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Chidamide (Epidaza),<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And others.<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Multiple Myeloma Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Multiple Myeloma Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Multiple Myeloma Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Multiple Myeloma Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Country-Specific Patient Population of Multiple Myeloma&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Multiple Myeloma&nbsp; Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Multiple Myeloma&nbsp; Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Multiple Myeloma&nbsp; Market Outlook<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Country-Wise Multiple Myeloma&nbsp; Market Analysis (2017&ndash;2030)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Multiple Myeloma&nbsp; Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Multiple Myeloma Pipeline&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&#8220;Multiple Myeloma Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Multiple Myeloma market. A detailed picture of the Multiple Myeloma pipeline landscape is provided, which includes the disease overview and Multiple Myeloma treatment guidelines.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Multiple Myeloma Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216;Multiple Myeloma&nbsp; Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Multiple Myeloma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=multiple-myeloma-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=multiple-myeloma-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast\u20142030\u2019 report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/multiple-myeloma-market-analysis-market-size-share-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_562885.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-562885","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/562885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=562885"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/562885\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=562885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=562885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=562885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}